CHICAGO — Eyes with proliferative diabetic retinopathy treated with monthly aflibercept experienced a stable retinal nonperfusion area after 1 year compared with patients treated with quarterly aflibercept, according to a speaker here.
“Through the 1-year endpoint of the phase 2 randomized RECOVERY trial, there was evidence of a dose response with reduction of retinal nonperfusion progression with monthly compared to quarterly dosing,” Charles C. Wykoff, MD, said at the American Society of Retina Specialists annual meeting.
Wykoff presented the 1-year results of the RECOVERY
Uncategorized